2026-10-25
Immunic, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,465 −1.17%
S&P 7,723 −0.27%
GOLD $4,035 −0.40%
BTC $81,733 +0.57%
VIX 16.46 −2.66%
latest tape · as of 16:04 UTC
The Screen · Healthcare · Biotechnology
Immunic, Inc.
IMUX · Nasdaq · USD · Market cap $91M · 92 employees
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Not yet scored7.41 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 16:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price7.41 USD at the 23 Oct 2026 close
- Our ratingFair value, current read distribution
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 19.62)
- Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 7.41 against the desk's fair-value range, base estimate 21.66, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 19.62, read 2026-10-28
- Ethical screen not yet scored
Price7.41 USD
Fair value21.66
Ethical score96.6/100
RatingFAIR VALUE
Our investment reviews on this name
2026-10-14Read Distribution8.19-9.5% to today ✓Markdown gives way to Distribution after a 12% slide in 12 days
2026-10-02Read Markdown9.32-20.5% to today ✓Accumulation gives way to Markdown after a 39% slide in 9 weeks
2026-08-02Read Accumulation15.16-51.1% to today Markup gives way to Accumulation after a 19% rise in 4 weeks
2026-07-02Read Markup12.77-42.0% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Immunic, Inc. holds its Distribution at $7.41. Consolidating, no directional conviction, held for 112 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 112 days |
| Price at the screen | $7.41 |
| Valuation | N/A trailing · -2.74 forward price to earnings |
| Values screen | Not scored · score 96.6 |
| Beta | 1.45 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 0.33% | Below 33% | Interest-bearing debt is just 0.3% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 8.78% | Below 33% | Cash held in interest-bearing accounts and securities is 8.8% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Immunic, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Immunic, clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads FAIR VALUE: it trades at roughly a 100% discount to our $21.66 fair value.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +305% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business. It trades close to our $21.66 fair value, so the easy discount is gone; you would be paying up for the quality.
| Forward P/E | -2.7x |
| EPS, trailing | -3.97 |
| EPS, forward | -2.43 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -138.2%not currently earning a positive return on equity |
| FCF yield | -56.57% |
| Debt to equity | 0.44minimal debt: a conservative balance sheet |
| Current ratio | 5.05comfortably covers its short-term bills |
| Beta | 1.45moves a little more than the market |
| Short interest, float | 0.16% |
| 52-week range | 5.06 - 17.43 |
| Market cap | $91M |
| Employees | 92 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeIMUX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-28
Distribution $7.10
+0.0% Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it strong buy, with a mean price target of $45.
2026-10-21
Distribution $7.10
-13.3% Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 39% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it strong buy, with a mean price target of $45.
2026-10-14
Distribution · changed $8.19
-12.1% Entry 7
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 12.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it strong buy, with a mean price target of $45.
2026-10-02
Markdown · changed $9.32
-43.3% Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 43.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it strong buy, with a mean price target of $45.
2026-09-02
Accumulation $16.45
+8.5% Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it strong buy, with a mean price target of $45.
2026-08-02
Accumulation · changed $15.16
+18.7% Entry 4
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 18.7% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it strong buy, with a mean price target of $45.
2026-07-18
Markup $12.77
+0.0% Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it strong buy, with a mean price target of $45.
2026-07-03
Markup $12.77
+0.0% Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02
Markup $12.77
Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Immunic to present four vidofludimus calcium abstracts at MSToronto2026 Yahoo Finance · 22d ago
- Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting Yahoo Finance · 22d ago
- Immunic to host virtual relapsing MS R&D Day on September 9 Proactive · 2 Sep 2026
- Immunic to host virtual relapsing MS R&D Day on September 9 Yahoo Finance · 2 Sep 2026
- Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 Yahoo Finance · 2 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
ATHEAlterity Therapeutics Ltd ADR
SPROSpero Therapeutics Inc
NTHINeOnc Technologies Holdings Inc
INOInovio Pharmaceuticals Inc
ANIXAnixa Biosciences, Inc.
BMEABiomea Fusion Inc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-06-13 | NASH DUANE D | Officer and Director | 20,000 | $16,694 | |
| 2025-06-05 | NEERMANN JOERG | Director | 100,000 | $76,700 | |
| 2025-06-05 | TARDIO JASON | President | 12,512 | $9,884 | |
| 2025-06-05 | TARDIO JASON | President | 12,512 | $9,884 | |
| 2025-06-04 | VITT DANIEL | Chief Executive Officer | 15,000 | $11,550 | |
| 2025-06-04 | VITT DANIEL | Officer and Director | 15,000 | $11,550 | |
| 2025-06-03 | WHALEY GLENN | Chief Financial Officer | 45,000 | $32,076 | |
| 2025-06-03 | RUDICK RICHARD ALAN | Director | 143,075 | $100,024 | |
| 2025-05-30 | WHALEY GLENN | Chief Financial Officer | 25,000 | $14,000 | |
| 2024-11-12 | RUDICK RICHARD ALAN | Director | 87,300 | $100,369 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $12.00 | -2.1% | · | $979 | -2.1% |
| 2 months | $11.70 | +0.4% | · | $1,004 | +0.4% |
| 3 months | $13.70 | -14.3% | · | $857 | -14.3% |
| 6 months | $6.56 | +79.0% | · | $1,790 | +79.0% |
| 1 year | $8.85 | +32.7% | · | $1,327 | +32.7% |
| 2 years | $12.30 | -4.5% | · | $955 | -4.5% |
| 3 years | $17.20 | -31.7% | · | $683 | -31.7% |
| 5 years | $142.00 | -91.7% | · | $83 | -91.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever IMUX does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.